Navigation Links
3M Discontinues Collaboration with Gen-Probe to Develop Molecular Tests for Healthcare-Associated Infections
Date:6/16/2008

rom estimates or projections contained in the forward-looking statements include but are not limited to, the risk that: (i) the companies will not be able to reach agreement on a new relationship, (ii) Gen-Probe's assays for HCAIs will not be successfully developed or integrated onto its next-generation instrument platforms, (iii) Gen-Probe may decide not to proceed with development of assays for HCAIs, (iv) new products, such as assays to detect HCAIs or new instruments, will not be cleared for marketing in the timeframes Gen-Probe expects, if at all, (v) the market for the sale of new products may not develop as expected, (vi) Gen-Probe may not be able to compete effectively, (vii) Gen-Probe may not be able to maintain its current corporate collaborations and (viii) competitors may challenge Gen-Probe's intellectual property rights. The foregoing describes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see the documents that 3M and Gen-Probe file with the SEC, including the most recent annual reports on Form 10-K and all subsequent periodic reports. Neither 3M nor Gen-Probe assume any obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Contact:

Gen-Probe 3M

Michael Watts Stephanie Sanderson

Senior director, investor relations and 3M Public Relations

corporate communications 651-733-8588

858-410-8673


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
2. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
3. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
4. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
5. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
6. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
7. SGX Provides Update on BCR-ABL Collaboration
8. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
9. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
10. Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement
11. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Lewisville, TX (PRWEB) September 18, 2014 ... PVC-C, a FM-4910 listed material, to stay competitive ... industries. These high-performance materials ultimately impact product ... company’s President and owner. , Established in 1980 ... held strong as many fabricators have left the ...
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  MEI Pharma, Inc. ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at BioCentury,s NewsMakers in the ... 8:30 a.m. Eastern time from the Millennium Broadway Hotel & ... live webcast of the presentation can be accessed at ...
(Date:9/18/2014)... SEATTLE , Sept. 18, 2014 /PRNewswire/ - Oncothyreon ... pricing of previously announced concurrent but separate underwritten offerings ... price to the public of $2.00 per share, for ... of its Series A Convertible Preferred Stock at a ... expected gross proceeds of $20 million. Each share of ...
(Date:9/18/2014)... Sept. 18, 2014   Sigma-Aldrich Corporation ... has entered into a new gene editing partnership ... Vector Core. Under the partnership, Sigma-Aldrich will provide ... design consultation, and dedicated gene editing bioinformaticians. ... editing-based research at the U-M Medical School. One ...
Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... Fla. -- Engineers at Florida State Universitys National High Magnetic ... that could literally shed new light on nanoscience and semiconductor ... Helix -- is operational in 2010, researchers will have the ... not only down the bore, or center, of the magnet, ...
... N.J., Oct. 31 Amicus Therapeutics,(Nasdaq: ... molecule,orally-active pharmacological chaperones for the treatment of ... the third quarter of 2007.,On a reported ... Accepted,Accounting Principles (GAAP), Amicus announced a net ...
... Calif., Oct. 31 Align,Technology, Inc. (Nasdaq: ... of straightening teeth without wires or brackets, has ... for Silicon Valley, a,ranking of the fastest growing ... region by Deloitte & Touche USA LLP, one ...
Cached Biology Technology:Let there be light: new magnet design continues magnet lab's tradition of innovation 2Amicus Therapeutics Announces Third Quarter 2007 Financial Results 2Amicus Therapeutics Announces Third Quarter 2007 Financial Results 3Amicus Therapeutics Announces Third Quarter 2007 Financial Results 4Amicus Therapeutics Announces Third Quarter 2007 Financial Results 5Amicus Therapeutics Announces Third Quarter 2007 Financial Results 6Amicus Therapeutics Announces Third Quarter 2007 Financial Results 7Amicus Therapeutics Announces Third Quarter 2007 Financial Results 8Align Technology, Inc. Ranked 23rd in Deloitte's Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies 2Align Technology, Inc. Ranked 23rd in Deloitte's Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies 3
(Date:9/19/2014)... a newly discovered hadrosaur with a truly ... Rhinorex condrupus by paleontologists from North Carolina ... what is now Utah approximately 75 million years ... which translates roughly into "King Nose," was a ... hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs are usually ...
(Date:9/19/2014)... A new resource unveiled today by researchers from ... College Dublin provides both experienced and aspiring researchers ... build, and operate robots made from soft, flexible ... printing, laser cutters, and other advances in manufacturing ... important field. Using principles drawn from conventional rigid ...
(Date:9/19/2014)... of Oklahoma biology professor will study the unique bioelectric ... could eventually benefit people,s health. The OU researcher ... energy required to produce the signals used to map ... signals at a rate of 500-600 discharges a second ... the electric fish are extreme, but necessary for survival. ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Soft robotics 'toolkit' features everything a robot-maker needs 2
... Microbial fuel cells, chemical sensors for your iPhone, and ... batteries, safer nuclear power, and new crime scene investigation ... the science of materials, interfaces, and processing. Detailed press ... 60th International Symposium & Exhibition will take place Oct. ...
... The harmful effects of increasingly popular designer cannabis products ... but now a group of researchers is reporting progress ... published in the ACS journal Analytical Chemistry , ... physicians diagnose and treat the thousands of young adults ...
... This news release is available in French . ... Montreal and the Institut universitaire de gratrie de Montral examined ... without mild cognitive impairment (MCI) at the early stages of ... more cortical thinning and subcortical atrophy over time compared with ...
Cached Biology News:AVS science symposium in Long Beach Oct. 27 -- Nov. 2 2
... 8-iso PGE2 is one of several isoprostanes ... is a potent renal vasoconstrictor in the rat. ... with IC50 values of 0.5 and 5 µM, ... the rat at a concentration of 4 mg/kg/min, ...
... The Centra-CL5R multi-purpose centrifuge offers ... a large assortment of rotor options, ... of laboratory applications., Maximum Versatility , ... 21,000 xg) angle rotors or high-volume (4 ...
...
... The Turn & Cast submarine gel systems used gasketed ... the gel in the tank. Turn it back and ... For added convenience, each Turn & Cast tray is ... near the edge of the tray and one in ...
Biology Products: